James Gruber
Director of Finance/CFO bij ETON PHARMACEUTICALS, INC.
Vermogen: 13 496 $ op 31-03-2024
Profiel
James R.
Gruber is currently the Chief Financial Officer, Secretary & Treasurer at Eton Pharmaceuticals, Inc. He previously worked as the Vice President & Controller at Horizon Therapeutics, Inc. Gruber received an undergraduate degree from Indiana University and an MBA from Kellogg School of Management.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 13-02-2024 | 3 599 ( 0.01% ) | 13 496 $ | 31-03-2024 |
Actieve functies van James Gruber
| Bedrijven | Functie | Begin |
|---|---|---|
| ETON PHARMACEUTICALS, INC. | Director of Finance/CFO | 11-04-2022 |
Eerdere bekende functies van James Gruber
| Bedrijven | Functie | Einde |
|---|---|---|
Horizon Therapeutics, Inc.
 Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Comptroller/Controller/Auditor | - |
Opleiding van James Gruber
| Indiana University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ETON PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Health Technology |
